Physician
Hematology
Dr. Phillip Scheinberg, MD
|
|
Give Review
Dr. Phillip Scheinberg is an expert in the field of Hematology. Phillip Scheinberg has written publications. He has 52 publications published with PubMed. The lastest publication is: 'Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.'
Publications
- "Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.
- Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
- Long-term Outcome of Fludarabine-Based Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Debilitating Paroxysmal Nocturnal Hemoglobinuria.
- Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia.
- Eltrombopag restores tri-lineage hematopoiesis in refractory severe aplastic anemia which can be sustained on discontinuation of drug.
- Thymus transplantation restores the repertoires of forkhead box protein 3 (FoxP3)+ and FoxP3- T cells in complete DiGeorge anomaly.
- Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
- Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis.
- Stem-cell transplantation for autoimmune diseases.
- Regulatory T-cell depletion does not prevent emergence of new CD25+ FOXP3+ lymphocytes after antigen stimulation in culture.
- Clonotype and Repertoire Changes Drive the Functional Improvement of HIV-Specific CD8 T Cell Populations under Conditions of Limited Antigenic Stimulation.
- Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.
- Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.
- Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.
- Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.
- Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells.
- Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes.
- T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.
- Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.
- Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on sev...
- Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia.
- Posterior segment ophthalmic complications of aplastic anemia.
- Immunosuppression or immunostimulation for aplastic anemia? A blast from the past.
- Th17 immune responses contribute to the pathophysiology of aplastic anemia.
- Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine.
- Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab.
- Granulocyte transfusions in severe aplastic anemia: an eleven-year experience.
- The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the do...
- Infections in patients with aplastic anemia.
- Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions.
- Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study.
- Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia.
- TCR beta-chain sharing in human CD8+ T cell responses to cytomegalovirus and EBV.
- High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow.
- Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobi...
- Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers.
- Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers.
- Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine.
- Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections.
- Aplastic anemia.
- Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
- Severe menorrhagia associated with thrombocytopenia.
- Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patients.
- The clonal composition of human CD4+CD25+Foxp3+ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements.
- Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.
- Apparent hemolysis following intravenous antithymocyte globulin treatment in a patient with marrow failure and a paroxysmal nocturnal hemoglobinuria clone.
- Current concepts in the pathophysiology and treatment of aplastic anemia.
- Alloreactive T cell clonotype recruitment in a mixed lymphocyte reaction: implications for graft engineering.
- Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia.
- Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil.
- Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab).
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
National Institutes of Health Clinical Center -
Mount Sinai Medical Center of Florida
Helpful Reviews
Similar Doctors
|
|
Ramaprasad Srinivasan, MB
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Metin Kurtoglu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maurcio Burotto Pichun, MD |
|
|
Dr. Philip M. Arlen, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Elizabeth M. Kang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark E. Sobel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stefania Pittaluga, MD |
|
|
Dr. Frederick A. Dorr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy B. Bernstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Morteza Moussavi, MD |
|
|
Dr. Erin A. Larkins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carolyn B. Hendricks, MD
This Doctor is OpenDoctor Recommended.
|